A private placement of Series F convertible preferred stock has brought in about $7 million in gross proceeds for NeuroMetrix. The proceeds, which will be provided in two tranches, will be used for general working capital purposes, as well as for continuing US commercialization of the Quell over-the-counter wearable pain relief device.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.